secwatch.observer — SEC 8-K summary
======================================

Issuer:     BiomX Inc. (PHGE)
CIK:        0001739174
Form:       8-K
Filed at:   2024-03-18T23:59:59+00:00
Accession:  0001213900-24-023201
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.01, 1.01, 3.02, 3.03, 5.03, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BiomX completes acquisition of Adaptive Phage Therapeutics, appoints new directors
--------------------------------------------------------------------------------

- On March 15, 2024, BiomX closed acquisition of Adaptive Phage Therapeutics (APT) per merger agreement filed March 6.
- Issued warrants for 250,000 common shares at $5.00 to APT's landlord in connection with lease amendment.
- Three prior directors (Lynne Sullivan, Jason Marks, Michael Dambach) resigned effective immediately before closing.
- Appointed Dr. Jesse Goodman, Jonathan Leff, and Gregory Merril to the board; Goodman and Merril as Class II, Leff as Class III.
- Consummated a previously announced private placement of Series X preferred stock and warrants concurrently with the closing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739174/000121390024023201/0001213900-24-023201-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739174/000121390024023201/ea0201977-8k_biomx.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-023201

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer